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Introduction
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults, with >50,000 patients currently living with the disease (1, 2) . Although patients with GBM may undergo aggressive surgical resection, irradiation and chemotherapy, the overall survival remains at only 14.6 months post-diagnosis (3) . GBM has been genomically stratified into four major subgroups: 1) neural, 2) pro-neural, 3) classical and 4) mesenchymal (4) . Different subtypes arise due to distinct pro-oncogenic events, possess novel response rates to therapy and show diverse patterns of T cell infiltration (5) . Given the heterogeneity of GBM, it has been a challenge to find therapeutically-targetable genes that are expressed by all four genomic subtypes, but not in untransformed cells. Indoleamine 2,3 dioxygenase 1 (IDO) is a tryptophan catabolic enzyme not normally expressed in the CNS parenchyma at appreciable levels (6), but is induced in 90% of GBM (7) .
Moreover, higher IDO expression is more often observed in GBM when compared with lowgrade glioma (8) , suggesting that the degree of transformation may play a role in IDO expression levels. Moreover, GBM patients with higher IDO expression levels exhibit a shorter overall survival. Recent work from our laboratory has identified that IDO expression by brain tumor cells, rather than other cells capable of expressing IDO, is critically-important in tumor-induced suppression of the anti-tumor response (9) . This was an unexpected finding given that in peripheral tumor models, IDO expressed by dendritic cells appears to play a critical role in suppressing the anti-tumor immune response (10) (11) (12) . (18, 19) . The latter component is a potently immunosuppressive subset that in GBM is characterized by the constitutively high level of CTLA-4, GITR and is predominantly represented as being thymus-derived (20) . Based on previous studies in peripheral tumor models demonstrating the impact of IDO on Treg activation (21) , expansion (22) and/or recruitment (23), we recently asked if there was a dominant cell type that required IDO to regulate Treg levels in brain tumors (9) . Our original hypothesis assumed that dendritic cell (DC)-expressed IDO would be required, based on previous work showing their role in Treg modulation (10, 21, 24) . However, upon more careful examination, while IDO-expressing DCs control Treg expansion, this mechanism depends on the conversion of CD4 (25) (26) (27) . Given that glioma-resident Treg are primarily thymusderived (20) , this likely explains why IDO -/-DC failed to impact Treg levels in brain tumors.
Here, we first extend our previous observations by determining the immunodominance of IDO-competent and IDO-deficient malignant glioma, ultimately revealing that timing of tumor implantation plays a significant role in tumor rejection. Next, we determined the therapeutic impact of inhibiting IDO, alone, or when combined with the current standard-of-care therapy, Temozolomide (TMZ; Temodar), unexpectedly revealing that the enzymatic inhibition of IDO does not play a crucial role in significantly increasing overall survival from malignant glioma.
Importantly, we tested the individual and combined impact of inhibiting CTLA-4, PD-L1, and IDO in models of established glioma, demonstrating a robust decrease in tumor-resident Treg concurrent with increased survival when all three targets were inhibited simultaneously.
However, when we tested the impact of a similar strategy in an aggressive intracranial melanoma model, only a modest effect on survival was observed. Collectively, these data significantly between the ages of 6 and 8 weeks. All mouse strains used in the included studies were on the C57BL/6 background and were provided autoclaved food pellets and water ad libitum. All surgical procedures were completed in accordance with National Institutes of Health guidelines on the care and use of laboratory animals for research purposes. All studies performed on mice were approved by the IACUC of the University of Chicago. Mice were euthanized by cervical dislocation. GL261 and B16-F10 cells were obtained from the NCI Frederick National Tumor Repository Lab (no authentication of the cell lines was conducted) and cultured in Dulbecco's modified Eagle medium supplemented with 10% fetal calf serum as well as streptomycin (100 mg/ml) and penicillin (100 U/ml) at 37°C in a humidified atmosphere of 95 % air/5 % CO 2 . All cell culture products were purchased from Gibco Invitrogen (Carlsbad, CA).
Methods

Mice and cell lines
C57BL
Mouse orthotopic intracranial-injection model
A detailed description can be found in the Supplemental Materials and Methods section.
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Research. A detailed description can be found in the Supplemental Materials and Methods section.
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Statistics. Data were analyzed using Prism 4.0 software (GraphPad Software). Experiments were repeated at least two times each. Data are represented as the mean ± SEM for all figure panels in which error bars are shown. The P values represent ANOVA for groups of 3 or more, whereas 2-tailed unpaired Student t tests were used for paired groups. A P value of less than 0.05 was considered statistically significant.
Results
The role of IDO and antigen specificity in glioma immunity
The genetic ablation of IDO in glioma cells results in the spontaneous rejection of brain tumors mediated by T cells (9) . Previous work demonstrating that the majority of patient GBM specimens are >50% positive for IDO (7) suggests that this tryptophan catabolic enzyme tonically maintains suppression of the anti-tumor response. To determine the minimum number In mice already bearing IDO-deficient tumors, when IDO-competent glioma cells were implanted early (ie. 7 days post-ic.), 100% of mice survived, whereas a later re-challenge with IDO-competent glioma cells (ie. 32 dp-ic.) led to only 40% of mice surviving (P<0.001, respectively). These data highlight the contextual nature of the anti-tumor immune response mediated by IDO-deficient glioma cells and suggest that timing of re-challenge plays a critical role with regard to overcoming tumor-induced immunosuppression and consequent effects on survival.
Given the potent effects of glioma cell-specific IDO-deficiency on the induction of productive tumor immunity, we next wondered if this effect required antigen specificity or whether the non-specific presence of CD4 + T cells was sufficient for increasing overall survival.
As expected, Figure 1C 
IDO expression and combinatorial targeting with temozolomide in glioma
Previous work from peripheral tumor models has shown that inhibiting IDO with the well-characterized molecular agent, 1-methyltryptophan (1-MT), requires the addition of a chemotherapeutic agent to provide a significant antitumor response (10) . To address this, we hypothesized that 1-MT would synergize with temozolomide (TMZ), the current standard-ofcare chemotherapeutic agent for patients with glioblastoma, to achieve a synergistic antitumormediated survival benefit. As shown in Figure 2A ,B, neither L1-MT nor D1-MT in gliomabearing mice significantly impacted overall survival, when compared to control untreated mice with a median survival of 24.5 days post-ic. In contrast, the treatment of mice with TMZ, alone, led to an increased median survival of 37.5 days post-ic. (P<0.01). To our surprise, neither the addition of L1-MT nor D1-MT increased survival further, vs. treatment with TMZ, alone.
However, there was a small but significant survival advantage when D1-MT was coupled with TMZ, compared to L1-MT with TMZ, reflected by the median overall survival of 46-vs. 35-dpic (P<0.05).
Given the surprisingly low level of efficacy upon treatment with 1-MT and TMZ, we hypothesized that additional tryptophan catabolic pathways are present in the context of glioma, given the recent evidence that IDO2 and TDO also play a role in tumor immunity (28, 29) . We 
A durable survival benefit after CTLA-4/PD-L1/IDO blockade in glioma
As an alternative to the combination of 1-MT with chemotherapy, we decided to pursue an approach that utilized 1-MT with CTLA-4 and PD-L1 blockade, instead, given the recent clinical success for end-stage melanoma patients administered with CTLA-4 and PD-1 mAbs (30) . As shown in Figure 3A ,B, 100% of untreated mice died with a median survival of 29 days post-ic. In contrast, 40%, 60% and 90% of mice treated with CTLA-4 mAb, PD-L1 mAb and coadministered CTLA-4 and PD-L1 mAbs, respectively, were still alive at 90 days post-ic., demonstrating an extraordinary survival benefit in glioma. To determine the impact of 1-MT on this approach, we analyzed mice bearing glioma and administered 1-MT, alone, or in combination with CTLA-4 mAb, PD-L1 mAb or co-administered with both CTLA-4 and PD-L1 mAbs ( Figure 3C ). Excitingly, 100% of mice treated with the triple therapy showed durable (19) , suppress the cytotoxic effector arm (32) and promote pathogenesis in experimental brain tumor models (18, 20, 33) . Therefore, depleting them directly or utilizing immunotherapy to neutralize their presence is a major on-going goal for improving standard-of-care treatment for GBM patients. As shown in Figure 4A 
blockade and that as Treg levels decrease due to the effects of triple immunotherapy, the CD4 + T cell expression for PD-1 and CTLA-4 changes commensurately.
CTLA-4/PD-L1/IDO blockade targets Treg and enhances survival from established glioma
Since our previous observation in smaller, less-established brain tumors suggested the triple therapy primarily decreased Treg cells, we wondered whether this effect would be maintained in larger, more well-established glioma; a time point that co-incides with brain tumors that are ≥ 2 mm in diameter (9) . As shown in Figure 5A ,B, there was a dramatic decrease in Treg levels from 38 ± 2% in untreated mice to 5.3 ± 1% in mice treated with triple therapy (P<0.001), which was reversed with the addition of TMZ back to 39 ± 4% (P<0.001).
Importantly, the triple therapy decreased Treg levels, when compared to dual treatment with CTLA-4/PD-L1 mAbs (P<0.05), suggesting that all three targets require therapeutic modulation to significantly affect this T cell subset in glioma. Interestingly, triple therapy also decreased brain-resident Tc levels, when compared to untreated mice, suggesting a possible overall reduction in inflammation-mediated by this approach. Importantly, this effect did not translate into differences in the level of CD44 Figure 6B ) (36) . When the GL261 and B16-F10 cell lines were analyzed, in vitro, for PD-1, GITR and PD-L1, quantifiable differences in GITR and PD-L1 were observed after stimulation with IFN-γ ( Figure 6C ). However, whether these differences affect Treg accumulation has yet to be established. To determine the effects of our triple immunotherapeutic approach against intracranial melanoma, we began immunotherapy at 3 days post-ic. in WT mice given the known aggressiveness of B16-F10 cells ( Figure 6D ). To our surprise, 1-MT alone (P<0.01), CTLA-4/PD-L1 blockade (P<0. 01), as well as combining all three reagents (P<0.001) increased overall survival. However, the overall benefit was limited to days, rather than months, as we had observed in GL261 cell-based brain tumors. Moreover, no difference in overall survival was found when a similar approach was used in IDO -/-mice ( Figure   6E ), nor when that approach was further combined with GITR and Lag-3 mAbs. These data suggest that the efficacy of inhibiting CTLA-4, PD-L1 and IDO in brain tumors will depend on context and based on the data we have presented here, will be more effective in tumors reliant on Treg accumulation, rather than aggressive tumors known to migrate and evade the immune response by alternative mechanisms. productive tumor immunity (10), we chose to study the treatment of glioma with 1-MT in combination with TMZ. We found that both levorotary (L) and dextrorotary (D) stereoisomers of 1-MT were ineffective at increasing overall survival from glioma burden when administered at 2 mg/mL in the drinking water. However, when both D1-MT and L1-MT were combined at 5 mg/mL they showed a significant anti-tumor effect, possibly reflecting a higher dosing requirement due to poor blood brain barrier permeability. Interestingly, when either L1-MT or D1-MT were co-administered with TMZ under the dosing regimen used in this study, neither combinatorial regimen increased survival when compared to mice treated with TMZ alone. This suggests that, in contrast to peripheral tumor models, the synergism between IDO inhibition and glioma-induced death may differ in sensitivity towards this therapeutic regimen. Alternatively, the lack of synergistic anti-tumor effect could be due to repeated and frequent dosing with TMZ, which may abrogate the establishment of a productive immune response. Another possible explanation includes compensation due to kynurenine production by IDO2 and/or TDO. In support of this hypothesis, we found that all three mammalian tryptophan catabolic enzymes, IDO1, IDO2 and TDO, were expressed in brain tumors. Recent evidence suggests that both IDO2 and TDO contribute to the regulation of immunity (42) and/or progression of glioma (43) .
Given that 1-MT and TMZ did not produce beneficial results when compared to TMZ, alone, we hypothesized that coupling IDO inhibition with the regulation of other powerful immunomodulatory mediators would produce a synergistic survival response in glioma-bearing 
nervous system (CNS), a site normally considered to be relatively immune privileged. Much to our surprise, the simultaneous therapeutic inhibition of CTLA-4 and PD-L1 at 1 week following glioma cell implantation led to a remarkably high survival rate of 90% in glioma-bearing mice.
Notably, this survival was durable over a 90-day period of observation. The addition of 1-MT to CTLA-4 and PD-L1 blockade was also associated with a high survival rate of 100% in gliomabearing mice. Notably, the survival benefit induced by triple immunotherapy was completed abrogated when the immune system was depleted for CD4 + and/or CD8 + T cells. This implies that there is a coordinated mechanism of action between both T cell subsets to carry out effective glioma immunity. However, the temporal requirement after therapeutic initiation for each T cell subtype, which cells they must interact with in the tumor microenvironment and whether those interactions mediate direct or indirect antitumor effects, have yet to be determined.
One unexpected finding from our study was that CTLA-4, PD-L1 ± IDO blockade in mice deficient for peripheral IDO (ie. non-glioma derived) showed decreased overall survival, when compared to WT mice. This is a somewhat paradoxical observation given the recent finding that host-derived IDO plays a critical role in anti-tumor immunity when coupled with either CTLA-4 or PD-1 blockade (31). However, it is important to keep in mind that what is often observed in the CNS, regardless of the presence or absence of neoplasm, does not recapitulate an identical response, peripherally. This is likely due, in part, to the presence of the blood brain barrier, lack of a developed lymphatic system, the normally low expression of MHC class II, as well as the different stromal cells within the CNS parenchyma.
We found that, regardless of early or late blockade for CTLA-4, PD-L1 and IDO, Treg levels were overall decreased. Interestingly, the late administration of immunotherapy also induced a decrease in brain tumor-infiltrating Tc. This latter observation has potentially 
important implications related to the overall inflammatory state IN the brain. Theoretically, any immunotherapy will generate some degree of inflammation associated with the production of pro-inflammatory cytokines and cell death associated with tumor rejection. Thus, a therapy that is effective for killing tumor cells, but recruits fewer leukocytes to the CNS, is highly desirable. This is particularly notable since the common way to decrease inflammation in the CNS for GBM patients is by administering Decadron, a glucocorticoid that will likely marginalize an active T cell-mediated response. Thus, while overall survival is similar between dual and triple therapeutic approaches, the additional advantage of decreased inflammatory cell infiltration warrants further investigation. CTLA-4 and PD-L1 blockade. By coupling this therapeutic regimen with 1-MT, we were able to reduce Treg and Tc levels in established brain tumors with similar levels of overall survival and durable efficacy. Since clinical-grade analogs are available for all three agents that we tested, this strategy has high therapeutic value for patients with GBM. Whether this approach will be equally effective for those patients that are initially diagnosed versus those who present with recurrent tumors has yet to be explored and is difficult to model experimentally. Also, our data suggests that concomitant administration of CTLA-4/PD-L1/IDO blockade and TMZ is not advantageous. Accordingly, we plan to determine whether staggering the treatments avoids therapeutic abrogation in the future. Ultimately, this work serves a proof-of-concept that this type of approach works and is relevant for treating patients with incurable malignant glioma. shown as mean ± SEM. *P < 0.05; **P < 0.01; ***P < 0.001.
